×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
FDA Approves Lilly's Tirzepatide for Obesity
FDA's Ongoing Evaluation of GLP-1 RAs: No Clear Link Found Between Medication and Suicidal Thoughts or Actions
GLP-1 Drugs and Suicidal Thoughts: A Comprehensive Review by Regulators
GLP-1 RAs and Gastroparesis (Stomach Paralysis)
GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
How GLP-1 Receptor Agonists Can Help You Manage Type 2 Diabetes
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Lilly Prepares for High Demand With $550M Stockpile of Oral GLP-1
Lilly’s Once-Daily Oral GLP-1 Pill Shows Promise for Type 2 Diabetes
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
Managing Blood Sugar with GLP-1 Medications: Foods to Avoid and Healthier Alternatives
Managing Type 2 Diabetes: The Power of Combining GLP-1 Medicines with FreeStyle Libre Technology
Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management
Novo Nordisk Strikes $2 Billion Deal for Potential Rival to Lilly’s Triple Agonist Drug
Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
Teva Launches Authorized Generic of Victoza (liraglutide) in the U.S.
The Dual Roles of GLP-1 and GLP-2 in Metabolic Health
Page 1 of 2
1
2
Articles
Articles
All News
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
September 2025
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Dexcom Introduces Smart Basal at EASD 2025
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
August 2025
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Teva Launches First Generic GLP-1 for Obesity
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Signos Press Release Raises Questions About FDA Clearance Claims
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
FDA Approves Wegovy for MASH Treatment
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
July 2025
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
